Company Announcements

Result of AGM

Source: RNS
RNS Number : 2552J
Hikma Pharmaceuticals Plc
25 April 2022
 

 

Hikma Pharmaceuticals PLC

Results of 2022 Annual General Meeting

LONDON, 25 April 2022  Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Annual General Meeting ("AGM"), held at 1 New Burlington Place, W1S 2HR, London on 25 April 2022 commenced at 1:00 pm. Resolution 15 was withdrawn from the business of the meeting and all the proposed resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 14 were passed as ordinary resolutions and Resolutions and 16 to 20 were passed as special resolutions.

The shareholder support for the re-election of the Chair of the Nomination and Governance Committee (resolution 8) has reduced from circa 97% in 2021 to 69% today. Following feedback from shareholders prior to the meeting, the Board understands that this was due to the level of female representation on the board falling to 22% as at the end of the AGM following the retirement of Dr. Pamela Kirby.  The Board had envisaged that Dr. Kirby would step down in 2023 but understands that she wished to move on earlier than anticipated.  The Board is in the process of reviewing candidates to raise the level of female representation to meet or exceed its target of 33%.  The Board has noted the recent announcement from the FCA regarding gender diversity and is taking steps to ensure that these requirements are met within the established timeframe.  The Board will provide an update on progress within six months of the AGM and in the next annual report.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the FCA's Electronic Submission System and will be available from the National Storage Mechanism.

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 23 February 2022) is set out below. The number of Ordinary Shares in issue on 25 April 2022 was 239,588,352.  There were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 226,755,119.

Resolution

Votes For

%

Votes Against

%

Total Cast

Withheld

1. To receive the 2021 report and accounts

171,860,023

100.00

2

0.00

171,860,025

1,357,656

2. To approve a final dividend of 36 cents per share

173,183,661

99.98

37,842

0.02

173,221,503

1,083

3. To re-appoint PricewaterhouseCoopers LLP as auditors

172,098,319

99.35

1,121,992

0.65

173,220,311

2,275

4.To authorise the Audit Committee to determine the auditors' remuneration

173,218,565

100.00

2,828

0.00

173,221,393

1,193

5. To re-elect Said Darwazah as a director

161,582,905

94.37

9,648,531

5.63

171,231,436

1,991,150

6. To re-elect Siggi Olafsson as a director

170,660,361

98.52

2,559,312

1.48

173,219,673

2,913

7. To re-elect Mazen Darwazah as a director

149,941,788

86.59

23,211,478

13.41

173,153,266

69,320

8. To re-elect Patrick Butler as a director

118,035,768

69.01

52,999,954

30.99

171,035,722

2,186,864

9.To re-elect Ali Al-Husry as a director

169,733,613

98.03

3,418,717

1.97

173,152,330

70,256

10. To re-elect John Castellani as a director

169,693,733

98.09

3,307,545

1.91

173,001,278

216,403

11. To re-elect Nina Henderson as a director

153,383,051

88.55

19,832,207

11.45

173,215,258

2,423

12. To re-elect Cynthia Flowers as a director

156,612,636

90.98

15,518,984

9.02

172,131,620

1,086,061

13. To re-elect Douglas Hurt as a director

153,843,021

88.82

19,370,952

11.18

173,213,973

3,708

14. To approve the remuneration report for the year ended 31 December 2021

157,785,532

91.09

15,426,369

8.91

173,211,901

5,780

15. Withdrawn

-

-

-

-

-

-

16. Authority to allot shares

164,319,344

95.46

7,812,300

4.54

172,131,644

1,086,037

17. To dis-apply pre-emption rights for general purposes

172,966,280

99.86

248,712

0.14

173,214,992

2,689

18. To dis-apply pre-emption rights for an acquisition or other capital investment

171,406,211

98.96

1,809,187

1.04

173,215,398

2,283

19. To authorise the Company to purchase its own shares

171,959,574

99.36

1,107,248

0.64

173,066,822

155,764

20. To authorise the Company to hold general meetings on no less than 14 clear days' notice

152,971,808

88.31

20,249,569

11.69

173,221,377

1,209

 

Declaration of final dividend

The dividend of 36 cents per share will be paid on 28 April 2022 to shareholders on the register on 18 March 2022.  Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling.  The exchange rate in respect of this dividend will be $1.3021 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa $1 to 0.709JD.

- ENDS -

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Peter Speirs

Company Secretary

 

+44 20 7399 2670

Susan Ringdal

EVP, Strategic Planning and Global Affairs

 

+44 20 7399 2670

 

 

 

 

 

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSEUFLIEESEDL